ArticleMolecular pharmaceutics2010
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Article in Molecular pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.Pharmacological reviews · 2022Review
- Glutathione-Biomolecules · 2022Article
- Article
- Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles.Acta pharmaceutica Sinica. B · 2019Review
- Inducing angiogenesis with the controlled release of nitric oxide from biodegradable and biocompatible copolymeric nanoparticles.International journal of nanomedicine · 2018Article
- Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.International journal of nanomedicine · 2018Article
- Enhanced dissolution of poorly soluble antiviral drugs from nanoparticles of cellulose acetate based solid dispersion matrices.Asian journal of pharmaceutical sciences · 2017Article
- Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Formulation of long-wavelength indocyanine green nanocarriers.Journal of biomedical optics · 2017Article
- Single-Step Assembly of Multimodal Imaging Nanocarriers: MRI and Long-Wavelength Fluorescence Imaging.Advanced healthcare materials · 2015Article
- Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641.Molecular pharmaceutics · 2015Article
- Polymer directed self-assembly of pH-responsive antioxidant nanoparticles.Langmuir : the ACS journal of surfaces and colloids · 2015Article
- Optimized zein nanospheres for improved oral bioavailability of atorvastatin.International journal of nanomedicine · 2015Article
- Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation.Molecular pharmaceutics · 2014Article
- Composite fluorescent nanoparticles for biomedical imaging.Molecular imaging and biology · 2014Article
- Gelation chemistries for the encapsulation of nanoparticles in composite gel microparticles for lung imaging and drug delivery.Biomacromolecules · 2014Article
- Nanocarriers for vascular delivery of anti-inflammatory agents.Annual review of pharmacology and toxicology · 2014Review
- Flash nanoprecipitation: particle structure and stability.Molecular pharmaceutics · 2013Article
- Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying.Pharmaceutical research · 2013Article
- Formation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitation.Molecular pharmaceutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We report the stabilization of the nitric oxide (NO) prodrugs and anticancer lead compounds, PABA/NO (O(2)-{2,4-dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl} 1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate) and "Double JS-K" 1,5-bis-{1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diol-2-ato}-2,4-dinitrobenzene, through their incorporation into polymer-protected nanoparticles. The prodrugs were formulated in block copolymer-stabilized nanoparticles with sizes from 220 to 450 nm by a novel rapid precipitation process. The block copolymers, with polyethylene glycol (PEG) soluble blocks, provide a steric barrier against NO prodrug activation by glutathione. Too rapid activation and NO release has been a major barrier to effective administration of this class of compounds. The nanoparticle stabilized PABA/NO are protected from attack by glutathione as evidenced by a significant increase in time taken for 50% decomposition from 15 min (unformulated) to 5 h (formulated); in the case of Double JS-K, the 50% decomposition time was extended from 4.5 min (unformulated) to 40 min (formulated). The more hydrophobic PABA/NO produced more stable nanoparticles and correspondingly more extended release times in comparison with Double JS-K. The hydrophobic blocks of the polymer were either polystyrene or polylactide. Both blocks produced nanoparticles of approximately the same size and release kinetics. This combination of PEG-protected nanoparticles with sizes appropriate for cancer targeting by enhanced permeation and retention (EPR) and delayed release of NO may afford enhanced therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.